A novel survival prediction signature outperforms PAM50 and artificial intelligence-based feature-selection methods

Area of Science:

• Genomics and Bioinformatics
• Computational Biology
• Oncology

Background:

• The super-proliferation set (SPS) is a breast cancer gene signature derived from a meta-analysis of 47 independent signatures, previously benchmarked on clinical survival data.
• Investigating the robustness and clinical utility of the SPS signature is crucial for advancing targeted breast cancer therapies.

Approach:

• The SPS signature's performance was evaluated on breast cancer cell lines from the Cancer Cell Line Encyclopaedia (CCLE).
• Principal Component Analysis (PCA) was employed to assess the prioritization of survival information over subtype information by SPS, comparing it against PAM50 and Boruta.
• SPS was used to extract higher-resolution 'progression' information, categorizing survival outcomes into clinically relevant stages.
• These 'progression' annotations were transferred to independent clinical datasets to demonstrate generalizability.
• Characteristic genetic profiles of each stage were analyzed to identify potential drug targets using gene signature reversal.

Key Points:

• SPS demonstrates superior prioritization of breast cancer survival information compared to PAM50 and Boruta AI algorithms.
• SPS facilitates the extraction of detailed 'progression' stages from survival data, enhancing clinical relevance.
• The 'progression' annotations derived from SPS are generalizable to independent patient datasets.
• Gene signature reversal identified efficacious drugs capable of modulating disease progression stages.

Conclusions:

• Meta-analytical approaches for gene signature inference are powerful tools in breast cancer research.
• The SPS signature offers significant clinical benefits by enabling translation to real-world patient data for targeted therapies.
• This study validates the clinical utility of SPS for personalized medicine in breast cancer treatment.